MDT

The upcoming report from Medtronic (MDT) is expected to reveal quarterly earnings of $1.54 per share, indicating a decline of 4.9% compared to the year-ago period. Analysts forecast revenues of $9.66 billion, representing an increase of 8.3% year over year. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. Given this perspective, it's time to examine the average forecasts of specific Medtronic metrics that are routinely monitored and predicted by Wall Street analysts. The combined assessment of analysts suggests that 'Net Sales- Other' will likely reach $19.75 million. The estimate suggests a change of -36.3% year over year. According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Neuroscience' should come in at $2.78 billion. The estimate suggests a change of +6.1% year over year. Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Cardiovascular' should arrive at $3.76 billion. The estimate suggests a change of +12.6% year over year. The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Medical Surgical' of $2.26 billion. The estimate indicates a change of +2.1% from the prior-year quarter. The average prediction of analysts places 'Net Sales- World Wide Revenue- Diabetes' at $811.59 million. The estimate points to a change of +11.5% from the year-ago quarter. The consensus among analysts is that 'Net Sales- World Wide Revenue- Cardiovascular- Structural Heart & Aortic' will reach $1.00 billion. The estimate indicates a change of +6% from the prior-year quarter. It is...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic (MDT) heads into its fourth quarter fiscal 2026 earnings on June 3 with several moving pieces, including completed and planned acquisitions, new FDA clearances, and a voluntary Class II software recall. See our latest analysis for Medtronic. The share price has been under pressure ahead of the earnings release, with a 30 day share price return down about 6.9% and a 90 day share price return down almost 19.7%, even though the 3 year total shareholder return is still slightly positive. Recent headlines, including the planned SPR Therapeutics acquisition, the CathWorks deal, the Stealth AXiS clearance, leadership changes, and the SynchroMed Flex software recall, give investors plenty to weigh as they reassess Medtronic’s growth drivers and risk profile around the upcoming results. If medical devices and robotics are on your radar, this could be a good moment to scan the broader opportunity set and see what stands out in 34 healthcare AI stocks With the stock down sharply over the past quarter and trading at a discount to both analysts’ average target and some intrinsic value estimates, is Medtronic offering a value entry point, or is the market already discounting its future growth? Medtronic’s narrative fair value of $95, compared with the last close at $77.60, frames the stock as underpriced and puts extra focus on what is driving that gap. Read the complete narrative. Want to see what underpins that valuation gap? The narrative leans on earnings power, cash generation, and a profit profile often associated with higher multiple sectors. Curious which specific assumptions carry the most weight in that $95 figure? Result: Fair Value of $95 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that 18.3% valuation gap can quickly narrow if regulatory setbacks or further product recalls hit sentiment, or if diabetes underperformance drags on group profitability. Find out about the key risks to this Medtronic narrative. With sentiment clearly mixed, this is a good moment to move quickly and stress test the assumptions yourself, starting with the 6 key rewards If you stop at just one stock, you risk missing other opportunities that could fit your goals even better, s...

Wall Street expects a year-over-year decline in earnings on higher revenues when Medtronic (MDT) reports results for the quarter ended April 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on June 3, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This medical device company is expected to post quarterly earnings of $1.56 per share in its upcoming report, which represents a year-over-year change of -3.7%. Revenues are expected to be $9.66 billion, up 8.3% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.39% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive po...

Medtronic (MDT) is expected to beat revenue and earnings estimates for its fiscal Q4, driven by new

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.23 per share, missing the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.72%. A quarter ago, it was expected that this medicine distributor would post earnings of $1.16 per share when it actually produced earnings of $1.14, delivering a surprise of -1.72%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Prestige Consumer Healthcare, which belongs to the Zacks Medical - Products industry, posted revenues of $281.62 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 4.29%. This compares to year-ago revenues of $296.52 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Prestige Consumer Healthcare shares have lost about 18.3% since the beginning of the year versus the S&P 500's gain of 8.1%. While Prestige Consumer Healthcare has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Prestige Consumer Healthcare was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market...

FitLife Brands Inc. (FTLF) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +21.43%. A quarter ago, it was expected that this company would post earnings of $0.25 per share when it actually produced earnings of $0.25, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. FitLife Brands , which belongs to the Zacks Medical - Products industry, posted revenues of $25.33 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 1.61%. This compares to year-ago revenues of $15.94 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. FitLife Brands shares have lost about 41.4% since the beginning of the year versus the S&P 500's gain of 8.8%. While FitLife Brands has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for FitLife Brands was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank...

Abbott ABT released its first-quarter 2026 financial results on April 16. The healthcare giant’s worldwide sales increased 7.8% year over year on a reported basis to $11.16 billion, while adjusted diluted earnings per share (EPS) of $1.15 reflected 6% growth. Both top and bottom lines modestly surpassed the respective Zacks Consensus Estimates. Despite the beat, shares tumbled nearly 4% in the pre-market hours shortly after the announcement. A major strategic highlight of the quarter was the completion of the $21 billion acquisition of Exact Sciences, which expands the company’s presence in the fast-growing cancer diagnostics market. As part of the transaction, Abbott assumed approximately $2.8 billion of Exact Sciences’ debt, of which $1.4 billion was repaid in March, and the remaining balance is expected to be settled by the year-end. The first quarter also partly reflected the impact of earlier-than-planned financing costs tied to the deal. Against this backdrop, the company has guided a 2026 sales growth outlook of 6.5% to 7.5%, incorporating full-year sales from Exact Sciences in both the prior and current year. Adjusted EPS of $5.38 to $5.58 includes $0.20 of dilution related to the acquisition. On May 11, ABT stock fell to a new 52-week low of $81.97 intraday, before closing the session slightly higher at $82.56. Over the past three months, Abbott shares have dropped 25%, underperforming the industry, the broader Medical sector and the S&P 500 Composite. The company also lagged peers such as Medtronic MDT and Tandem Diabetes Care TNDM, whose shares have dipped 22.6% and 22.3%, respectively. Image Source: Zacks Investment Research The technical indicator also points to a bearish trend. At current levels, ABT stock continues to trade below its 50 and 200-day simple moving averages. Image Source: Zacks Investment Research Although Abbott’s Diagnostics sales rose 2% on a comparable basis (total reported growth excluding foreign exchange impact), Rapid and Molecular Diagnostics business sales fell 10% due to lower demand for respiratory virus testing amid a significantly weaker respiratory season. Core Lab Diagnostics also continued to face challenging market conditions in China, partially offsetting the steady growth in diagnostic test sales on the Alinity platform across the United States, Europe and Latin America. Meanwhile, the newly formed Cancer Diag...

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology conference in Q2 2027 and subsequent marketing application submission to FDA and global regulatory agencies, assuming primary endpoints are met FDA granted a second Breakthrough Device Designation (“BDD”) for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemaker Virtue Trial sites progressing with site activation and patient enrollment acceleration continuing throughout 2026 Cash runway projected into Q4 2027 and through achievement of key upcoming clinical and regulatory milestones NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2026, and provided a business update highlighting momentum across the Company’s pivotal-stage programs for Atrioventricular Interval Modulation (“AVIM”) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) supported by the Company’s strong balance sheet. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed stated, “We continued to make meaningful advancements across our late-stage cardiovascular pipeline during the first quarter. Along with the achievement of recently announced important regulatory, clinical and financing milestones, we are pleased to provide clarity on the expected timeline for the BACKBEAT Trial highlighting objectives for enrollment completion, late-breaking clinical trial presentation, and plans for potential regulatory submissions by our strategic collaborator Medtronic. With increasingly strong momentum continuing in the BACKBEAT Trial and the AVIM Therapy program, and great progress for the Virtue Trial and Virtue SAB, our team is excited about the significant value inflection points that lie ahead for Orchestra BioMed.” Q1 2026 and Recent Business Highlights: Provided overall update on the BACKBEAT Trial timeline, targeting enrollment completion by the end of the third quarter...

InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +25.00%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.1, delivering a surprise of +42.86%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. InfuSystems Holdings, which belongs to the Zacks Medical - Products industry, posted revenues of $33.68 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 2.37%. This compares to year-ago revenues of $34.72 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. InfuSystems Holdings shares have added about 13% since the beginning of the year versus the S&P 500's gain of 7.6%. While InfuSystems Holdings has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for InfuSystems Holdings was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete...

ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease and accelerate time to treatment. CHICAGO, April 01, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electronic clinician notifications (ECNs) integrated into the electronic health record (EHR) significantly improve the timely evaluation and treatment of patients with significant aortic stenosis (AS) and mitral regurgitation (MR). Valvular heart disease is a leading cause of morbidity and mortality, yet it remains frequently undertreated. For patients with untreated symptomatic severe AS, mortality approaches 50% within just two years. Similarly, untreated severe MR carries a median survival of only five years. The ALERT trial was designed to determine if automated, AI-driven alerts could bridge this critical gap in care delivery. By leveraging the Tempus Next platform, which applies natural language processing to accurately extract findings from echocardiogram reports, the trial enabled real-time detection of significant disease and automatically delivered notifications with site-specific guideline-based care notifications directly to providers. The ALERT trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems and 35 hospitals. The study met its primary endpoint, demonstrating that automated ECN alerts were superior to usual care in a win ratio analysis (win ratio 1.27; P = .007), meaning patients in the alert group were 27% more likely to be evaluated by the multidisciplinary heart team or receive a valve intervention than those in the usual care group. By delivering actionable data directly to providers, the system facilitated a 40% relative increase in life-saving valve procedures (13.4% vs. 9.6%) and a 27% increase in multidisciplinary heart team evaluations (22.7% vs. 17.9%) within just 90 d...

Tempus AI (TEM) and Medtronic (MDT) said Wednesday an automated electronic notification platform sig

Medtronic (MDT) cut its fiscal 2026 non-GAAP earnings guidance to $5.50 to $5.54 a share from $5.62